Company Search:
Advanced Search
Sponsored Links
Mabion SA Company Snapshot
Mabion SA operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mabion SA with three other miscellaneous service companies in Europe: Sygnis Ag of Germany (2015 sales of 555,000.00 Euro [US$609,217.95 ] of which 55% was Other), Tigenix Nv of Belgium (537,000.00 Euro [US$589,459.53 ] of which 100% was Pharmaceuticals), and Hansa Medical AB which is based in Sweden (7.16 million Swedish Kronor [US$809,731.35 ] of which 100% was Biomedical & Drugs).

Sales Analysis. Sales increased substantially in 2015: Mabion SA reported sales of 2.73 million Polish New Zlotys (US$695.77 thousand) for the year ending December of 2015. This represents an increase of 229.4% versus 2014, when the company's sales were 829,661.00 Polish New Zlotys.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Mabion SA
  Stock Performance Chart for Mabion SA
  Stock Data: Recent Stock Performance:
  Current Price (10/21/2016): 77.70
(Figures in Polish New Zlotys)
1 Week 2.2%   13 Weeks -4.1%  
4 Weeks -1.6%   52 Weeks 65.3%  
Mabion SA Key Data:
  Ticker: MAB Country: Poland
  Exchanges: WAR Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2015 Sales 2,733,000
(Year Ending Jan 2016).
Employees: 40
  Currency: Polish New Zlotys Market Cap: 893,550,000
  Fiscal Yr Ends: December Shares Outstanding: 11,500,000
  Share Type: Akcje Closely Held Shares: 4,885,403
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.